File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Incidence of and mortality from cancer in hypertensive patients

TitleIncidence of and mortality from cancer in hypertensive patients
Authors
Issue Date1993
Citation
British Medical Journal, 1993, v. 306 n. 6878, p. 609-611 How to Cite?
AbstractObjectives - To assess incidence of and mortality from cancer in hypertensive patients taking atenolol, comparing the findings with two control populations and with hypertensive patients taking other drugs. Design - Retrospective analysis of patients first seen in the Glasgow Blood Pressure Clinic between 1972 and 1990. Patients' records were linked with the registrar general's data for information on mortality and with the West of Scotland Cancer Registry for information on incident and fatal cancers. Cancers were compared in patients and controls and in patients taking atenolol, β blockers other than atenolol, and hypotensive drugs other than β blockers. Subjects - 6528 male and female patients providing 54,355 years of follow up. Setting - Hypertension clinic in Glasgow. Main outcome measures - Observed numbers of cancers in clinic patients were compared with expected numberes derived from cancer rates in two control populations adjusted for age, sex, and time period of data collection. Results - Cancer mortality was not significantly different in clinic patients as a whole and controls. Incident and fatal cancers were not significantly increased in male or female patients taking atenolol. Cancer incidence did not rise in the clinic after a large increase in prescriptions for atenolol after 1976. Conclusion - This analysis does not suggest a link between atenolol and cancer.
Persistent Identifierhttp://hdl.handle.net/10722/151515
ISSN
2008 Impact Factor: 12.827
2015 SCImago Journal Rankings: 2.567
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHole, DJen_US
dc.contributor.authorHawthorne, VMen_US
dc.contributor.authorIsles, CGen_US
dc.contributor.authorMcghee, SMen_US
dc.contributor.authorRobertson, JWKen_US
dc.contributor.authorGillis, CRen_US
dc.contributor.authorWapshaw, JAen_US
dc.contributor.authorLever, AFen_US
dc.date.accessioned2012-06-26T06:24:10Z-
dc.date.available2012-06-26T06:24:10Z-
dc.date.issued1993en_US
dc.identifier.citationBritish Medical Journal, 1993, v. 306 n. 6878, p. 609-611en_US
dc.identifier.issn0959-8146en_US
dc.identifier.urihttp://hdl.handle.net/10722/151515-
dc.description.abstractObjectives - To assess incidence of and mortality from cancer in hypertensive patients taking atenolol, comparing the findings with two control populations and with hypertensive patients taking other drugs. Design - Retrospective analysis of patients first seen in the Glasgow Blood Pressure Clinic between 1972 and 1990. Patients' records were linked with the registrar general's data for information on mortality and with the West of Scotland Cancer Registry for information on incident and fatal cancers. Cancers were compared in patients and controls and in patients taking atenolol, β blockers other than atenolol, and hypotensive drugs other than β blockers. Subjects - 6528 male and female patients providing 54,355 years of follow up. Setting - Hypertension clinic in Glasgow. Main outcome measures - Observed numbers of cancers in clinic patients were compared with expected numberes derived from cancer rates in two control populations adjusted for age, sex, and time period of data collection. Results - Cancer mortality was not significantly different in clinic patients as a whole and controls. Incident and fatal cancers were not significantly increased in male or female patients taking atenolol. Cancer incidence did not rise in the clinic after a large increase in prescriptions for atenolol after 1976. Conclusion - This analysis does not suggest a link between atenolol and cancer.en_US
dc.languageengen_US
dc.relation.ispartofBritish Medical Journalen_US
dc.subject.meshAge Factorsen_US
dc.subject.meshAntihypertensive Agents - Adverse Effects - Therapeutic Useen_US
dc.subject.meshAtenolol - Adverse Effects - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHypertension - Drug Therapy - Epidemiology - Mortalityen_US
dc.subject.meshIncidenceen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasms - Epidemiology - Mortality - Pathologyen_US
dc.subject.meshRegistriesen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshScotland - Epidemiologyen_US
dc.subject.meshSex Factorsen_US
dc.subject.meshSmokingen_US
dc.subject.meshTime Factorsen_US
dc.titleIncidence of and mortality from cancer in hypertensive patientsen_US
dc.typeArticleen_US
dc.identifier.emailMcGhee, SM:smmcghee@hkucc.hku.hken_US
dc.identifier.authorityMcGhee, SM=rp00393en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid8461810-
dc.identifier.scopuseid_2-s2.0-0027404498en_US
dc.identifier.volume306en_US
dc.identifier.issue6878en_US
dc.identifier.spage609en_US
dc.identifier.epage611en_US
dc.identifier.isiWOS:A1993KQ85900017-
dc.identifier.scopusauthoridHole, DJ=13310293600en_US
dc.identifier.scopusauthoridHawthorne, VM=7006814057en_US
dc.identifier.scopusauthoridIsles, CG=7005519582en_US
dc.identifier.scopusauthoridMcGhee, SM=7003288588en_US
dc.identifier.scopusauthoridRobertson, JWK=7404532167en_US
dc.identifier.scopusauthoridGillis, CR=7102592203en_US
dc.identifier.scopusauthoridWapshaw, JA=7801493895en_US
dc.identifier.scopusauthoridLever, AF=7102361496en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats